185 related articles for article (PubMed ID: 10856098)
1. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
Norris B; Pritchard KI; James K; Myles J; Bennett K; Marlin S; Skillings J; Findlay B; Vandenberg T; Goss P; Latreille J; Rudinskas L; Lofters W; Trudeau M; Osoba D; Rodgers A
J Clin Oncol; 2000 Jun; 18(12):2385-94. PubMed ID: 10856098
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
Reyno L; Seymour L; Tu D; Dent S; Gelmon K; Walley B; Pluzanska A; Gorbunova V; Garin A; Jassem J; Pienkowski T; Dancey J; Pearce L; MacNeil M; Marlin S; Lebwohl D; Voi M; Pritchard K;
J Clin Oncol; 2004 Jan; 22(2):269-76. PubMed ID: 14722035
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy.
Aziz Z; Rehman A; Qazi S
Cancer Chemother Pharmacol; 1999; 44 Suppl():S9-S12. PubMed ID: 10602903
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
6. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
Vici P; Colucci G; Giotta F; Sergi D; Filippelli G; Perri P; Botti C; Vizza E; Carpino A; Pizzuti L; Latorre A; Giannarelli D; Lopez M; Di Lauro L
J Exp Clin Cancer Res; 2011 Apr; 30(1):39. PubMed ID: 21481280
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Nabholtz JM; Falkson C; Campos D; Szanto J; Martin M; Chan S; Pienkowski T; Zaluski J; Pinter T; Krzakowski M; Vorobiof D; Leonard R; Kennedy I; Azli N; Murawsky M; Riva A; Pouillart P;
J Clin Oncol; 2003 Mar; 21(6):968-75. PubMed ID: 12637459
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
Spielmann M; Dorval T; Turpin F; Antoine E; Jouve M; Maylevin F; Lacombe D; Rouesse J; Pouillart P; Tursz T
J Clin Oncol; 1994 Sep; 12(9):1764-70. PubMed ID: 8083698
[TBL] [Abstract][Full Text] [Related]
10. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
[TBL] [Abstract][Full Text] [Related]
11. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Biganzoli L; Cufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
J Clin Oncol; 2002 Jul; 20(14):3114-21. PubMed ID: 12118025
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
[TBL] [Abstract][Full Text] [Related]
16. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
17. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer.
Hegg R; Costa MA; Perdicaris M; Delgado GL; Cabral-Filho S; Malzyner A; Caponero R; Yamagushi N; Novaes N; Anelli A; Correa M; Nader L; Andrade C
Curr Med Res Opin; 2001; 16(4):225-34. PubMed ID: 11268706
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
20. Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study.
Hochster HS; Vogel CL; Burman SL; White R
Oncologist; 2001; 6(3):269-77. PubMed ID: 11423674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
